Synopsys 3Q Revenue, Profit Rise Amid Race to AI
By Denny Jacob
Synopsys posted slightly higher-than-expected revenue in its latest quarter as it benefits from companies racing to invest in artificial intelligence.
The provider of electronic-design-automation software reported fiscal third-quarter net income of $408.1 million, or $2.61 a share, up from $336.3 million, or $2.17 a share, a year earlier. Adjusted earnings were $3.43 a share, up from $2.70 and above the $3.28 expected by analysts polled by Factset.
Revenue rose to $1.53 billion from $1.35 billion. Analysts expected $1.52 billion.
"The complexity and pace of technology innovation is accelerating as silicon and systems companies race to capitalize on AI in this era of pervasive intelligence," Chief Executive Sassine Ghazi said.
Synopsys guided for revenue between $1.61 billion and $1.64 billion, and adjusted earnings per share between $3.27 and $3.32 in the fourth quarter ending Oct. 31. Analysts expected $1.62 billion and $3.25 a share in adjusted earnings.
For fiscal 2024, the company guided for revenue between $6.11 billion and $6.14 billion as well as adjusted earnings per-share between $13.07 and $13.12. Analysts polled by FactSet expected $6.13 billion and $12.96 a share in adjusted earnings.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
August 21, 2024 16:53 ET (20:53 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks